A PATIENT. A UNIQUE PROFILE. A PERSONALIZED THERAPY.
Precision Immunotherapy, Powered by AI.
WHO WE ARE
Likang Life Sciences is dedicated to precision cancer immunotherapy, using scientific innovation to address the biological differences between patients. By integrating AI, bioinformatics, and mRNA technology, we explore more targeted therapeutic strategies.
LEARN MORE
LNEA
AI-Powered Neoantigen Discovery Platform
LK101
Personalized Neoantigen Vaccine
LK201
Personalized T-Cell Therapy
FROM ONE PROFILE TO ONE TAILORED THERAPY
Every tumor is unique. Personalized immunotherapy begins with understanding its unique biology.
- PATIENT
- TUMOR SAMPLING
- GENE SEQUENCING
- AI NEOANTIGEN IDENTIFICATION
- PERSONALIZED THERAPY
- PATIENT
WHAT ARE NEOANTIGENS?
Neoantigens are tumor-specific protein fragments arising from mutations and absent from normal tissues.
Because they may be recognized as “non-self” by the immune system, they can serve as targets for personalized immunotherapy.
Every patient is unique. Deeper insights into tumor biology and immunity are driving cancer immunotherapy toward greater precision and personalization.
HISTORY OF IMMUNOLOGY AND TUMOR IMMUNITY
1893
Live bacteria and bacterial lysates were used to treat tumors—an approach known as “Coley’s toxins” (William B. Coley).
Contact Us
Get in touch to learn more about our technology and partnership opportunities